Product Specification Sheet

**Product Name:** BMS-708163 (Avagacestat)

**Catalog Number:** C2708

**Chemical Formula:** \( C_{20}H_{17}ClF_4N_4O_4S \)

**CAS #:** 1146699-66-2

**Molecular Weight:** 520.88

**Purity:** > 98%

**Appearance:** White

**Solubility:** Soluble in DMSO up to 50 mM

**Chemical Name:** (2R)-2-[N-(2-fluoro-4-[(1,2,4-oxadiazol-3-yl)benzyl]-4-chlorophenylsulfonamido)-5,5,5-trifluoropentanamide

**Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

**Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

**Handling:**
- To make 10 mM stock solution, add 0.192mL of DMSO for each mg of BMS-708163 (Avagacestat)
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:**

BMS-708163 (Avagacestat) is a potent and selective inhibitor for γ-secretase, especially at inhibiting cleavage of amyloid precursor protein (APP) to form amyloid-β (Aβ(1-40) (IC50=0.3nM) and Aβ(1-42) (0.27nM). BMS-708163 is “Notch sparing”, with more than 100 folds more selective for APP than for Notch protein (IC50 of 58nM).

BMS-708163 is developed for treating Alzheimer’s disease (AD). Oral administration of BMS-708163 significantly reduced Aβ(1-40) levels for sustained periods in brain, plasma, and cerebrospinal fluid in rats and dogs [1]. The results of Phase II clinical trial in mild-to-moderate AD patients demonstrated acceptable tolerability at a single-dose range of 0.3 to 800 mg with a biphasic effect on plasma Aβ(1-40) [2].

**Reference:**


For Technical Support: technical@cellagentech.com

*For research use only, not for clinical or diagnostic use.*